Algert Global LLC Acquires 102,670 Shares of Ralliant Corporation $RAL

Key Points

• Algert Global significantly increased its Ralliant stake by 439.9% in the second quarter, adding 102,670 shares to own 126,010 shares valued at approximately $9.3 million. Other major investors, including BlackRock, Viking Global and State Street, also established or expanded positions.
• Analyst sentiment is broadly positive, with a MarketBeat consensus rating of “Moderate Buy” and an average price target of $75.70. Recent targets range from $65 to $80, although Weiss Ratings maintained a sell rating.
• Ralliant reported quarterly EPS of $0.68, exceeding the $0.63 consensus estimate, on revenue of $567.8 million. The company declared a quarterly dividend of $0.05 per share, while its stock opened at $61.87 after declining 1.7%.

Algert Global LLC boosted its stake in shares of Ralliant Corporation (NYSE:RAL - Free Report) by 439.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 126,010 shares of the company's stock after buying an additional 102,670 shares during the period. Algert Global LLC owned approximately 0.11% of Ralliant worth $9,278,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Ralliant in the 2nd quarter valued at $1,039,481,000. Dodge & Cox increased its holdings in Ralliant by 13.3% during the 4th quarter. Dodge & Cox now owns 12,214,679 shares of the company's stock worth $621,849,000 after purchasing an additional 1,434,376 shares in the last quarter. Viking Global Investors LP bought a new position in Ralliant during the 2nd quarter worth about $257,200,000. Millennium Management LLC raised its stake in shares of Ralliant by 172.4% in the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company's stock valued at $253,175,000 after purchasing an additional 3,147,660 shares during the period. Finally, State Street Corp acquired a new stake in shares of Ralliant in the 2nd quarter valued at about $213,096,000.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Oppenheimer upped their price objective on Ralliant from $50.00 to $65.00 and gave the stock an "outperform" rating in a research report on Wednesday, May 13th. Evercore began coverage on Ralliant in a research report on Tuesday, June 9th. They issued an "outperform" rating and a $80.00 target price on the stock. Barclays increased their price target on Ralliant from $52.00 to $67.00 and gave the company an "overweight" rating in a research report on Wednesday, May 13th. Wall Street Zen raised Ralliant from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of Ralliant in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $75.70.

Ralliant Trading Down 1.7%

RAL stock opened at $61.87 on Wednesday. Ralliant Corporation has a one year low of $37.27 and a one year high of $75.41. The stock has a market cap of $6.85 billion, a price-to-earnings ratio of -5.70, a price-to-earnings-growth ratio of 2.34 and a beta of 1.60. The company has a fifty day moving average price of $68.69 and a two-hundred day moving average price of $56.04. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.00.

Ralliant (NYSE:RAL - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.63 by $0.05. The company had revenue of $567.80 million during the quarter. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Equities analysts anticipate that Ralliant Corporation will post 2.87 EPS for the current year.

Ralliant Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Tuesday, September 8th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 8th. Ralliant's dividend payout ratio (DPR) is currently -1.84%.

Insider Activity at Ralliant

In other Ralliant news, SVP Karen M. Bick sold 6,062 shares of the firm's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $72.00, for a total value of $436,464.00. Following the sale, the senior vice president owned 31,668 shares of the company's stock, valued at approximately $2,280,096. This trade represents a 16.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara S. Newcombe sold 12,936 shares of Ralliant stock in a transaction on Friday, August 14th. The shares were sold at an average price of $71.79, for a total value of $928,675.44. Following the completion of the transaction, the chief executive officer owned 251,967 shares in the company, valued at approximately $18,088,710.93. The trade was a 4.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is currently owned by company insiders.

Ralliant Company Profile

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

Want to see what other hedge funds are holding RAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ralliant Corporation (NYSE:RAL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source